Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | PKM | P14618 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | PKLR | P30613 | 4/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702474 | 0.87 | PKLR (0.76) | PKMPKLR | |
| SCHEMBL28023893 | 0.86 | NAMPT (0.61) | ALDH1A1PKMGAASMN1; SMN2MAPK1 | |
| SCHEMBL30880106 | 0.82 | PKLR (0.62) | ALDH1A1PKMGAASMN1; SMN2MAPK1 | |
| SCHEMBL2703686 | 0.81 | PKLR (0.70) | PKMPKLR | |
| SCHEMBL18753970 | 0.80 | ALDH1A1 (0.74) | ALDH1A1PKMGAASMN1; SMN2MAPK1 | |
| SCHEMBL2704269 | 0.79 | PKLR (0.65) | PKMPKLR | |
| SCHEMBL31224967 | 0.79 | PKLR (0.65) | PKMPKLR | |
| SCHEMBL2702295 | 0.79 | PKLR (0.65) | PKMPKLR | |
| SCHEMBL2702379 | 0.78 | PKLR (0.67) | PKMPKLR | |
| SCHEMBL2703003 | 0.78 | PKLR (0.65) | PKMPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10029987-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029987-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885PKM 6/4885GAA 1253/4885 |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885PKM 6/4885GAA 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.